{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:42:22Z","timestamp":1789771342854,"version":"4.0.1"},"reference-count":167,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Remarkable advances have been made in the pathophysiology, diagnosis, and treatment of antibody-mediated rejection (ABMR) over the past decades, leading to improved graft outcomes. However, long-term failure is still high and effective treatment for chronic ABMR, an important cause of graft failure, has not yet been identified. Chronic ABMR has a relatively different phenotype from active ABMR and is a slowly progressive disease in which graft injury is mainly caused by<jats:italic>de novo<\/jats:italic>donor specific antibodies (DSA). Since most trials of current immunosuppressive therapies for rejection have focused on active ABMR, treatment strategies based on those data might be less effective in chronic ABMR. A better understanding of chronic ABMR may serve as a bridge in establishing treatment strategies to improve graft outcomes. In this in-depth review, we focus on the pathophysiology and characteristics of chronic ABMR along with the newly revised Banff criteria in 2017. In addition, in terms of chronic ABMR, we identify the reasons for the resistance of current immunosuppressive therapies and look at ongoing research that could play a role in setting better treatment strategies in the future. Finally, we review non-invasive biomarkers as tools to monitor for rejection.<\/jats:p>","DOI":"10.3389\/fphar.2021.651222","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T02:37:03Z","timestamp":1618540623000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Therapies for Chronic Allograft Rejection"],"prefix":"10.3389","volume":"12","author":[{"given":"Min Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"32898","DOI":"10.1016\/j.transproceed.2020.10.050","article-title":"Chronic active antibody-mediated rejection following COVID-19 infection in a kidney transplant recipient: a case report","author":"Abuzeineh","year":"2020","journal-title":"Transplant. Proc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1097\/tp.0000000000001650","article-title":"Long-term outcomes of kidney transplantation in patients with high levels of preformed DSA","volume":"101","author":"Amrouche","year":"2017","journal-title":"Transplantation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1097\/tp.0000000000001321","article-title":"Establishing biomarkers in transplant medicine","volume":"100","author":"Anglicheau","year":"2016","journal-title":"Transplantation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1681\/asn.2016070797","article-title":"Antibody-mediated rejection due to preexisting versusDe NovoDonor-specific antibodies in kidney allograft recipients","volume":"28","author":"Aubert","year":"2017","journal-title":"Jasn"},{"key":"B5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/ctr.12535","article-title":"Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study","volume":"29","author":"Bachelet","year":"2015","journal-title":"Clin. Transpl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/tp.0000000000002002","article-title":"Prognostic value of the persistence of C1q-binding anti-HLA antibodies in acute antibody-mediated rejection in kidney transplantation","volume":"102","author":"Bailly","year":"2018","journal-title":"Transplantation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/tri.13613","article-title":"An extension of the RITUX\u2010ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody\u2010mediated rejection after renal transplantation","volume":"33","author":"Bailly","year":"2020","journal-title":"Transpl. Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1016\/s0140-6736(18)30984-x","article-title":"Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial","volume":"391","author":"Banham","year":"2018","journal-title":"The Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clinbiochem.2016.02.001","article-title":"Immune mechanisms of acute and chronic rejection","volume":"49","author":"Becker","year":"2016","journal-title":"Clin. Biochem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1053\/j.ackd.2019.12.002","article-title":"Complement-based therapy in the management of antibody-mediated rejection","volume":"27","author":"Bhalla","year":"2020","journal-title":"Adv. Chronic Kidney Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1432-2277.2012.01544.x","article-title":"IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up","volume":"25","author":"Billing","year":"2012","journal-title":"Transpl. Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1681\/asn.2016091034","article-title":"Cell-free DNA and active rejection in kidney allografts","volume":"28","author":"Bloom","year":"2017","journal-title":"Jasn"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1681\/ASN.V1341091","article-title":"Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury","volume":"13","author":"B\u00f6hmig","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.clinbiochem.2015.05.024","article-title":"Detection of alloantibody-mediated complement activation: a diagnostic advance in monitoring kidney transplant rejection?","volume":"49","author":"B\u00f6hmig","year":"2016","journal-title":"Clin. Biochem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/ajt.15067","article-title":"Dual targeting: combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients","volume":"19","author":"Burghuber","year":"2019","journal-title":"Am. J. Transpl."},{"key":"B16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/tri.12864","article-title":"Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation","volume":"30","author":"Caillard","year":"2017","journal-title":"Transpl. Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ki.2015.275","article-title":"The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation","volume":"89","author":"Calp-Inal","year":"2016","journal-title":"Kidney Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/ajt.14987","article-title":"Longitudinal profile of circulating T follicular helper lymphocytes parallels anti-HLA sensitization in renal transplant recipients","volume":"19","author":"Cano-Romero","year":"2019","journal-title":"Am. J. Transpl."},{"key":"B19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.kint.2019.01.033","article-title":"Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence","volume":"96","author":"Cherukuri","year":"2019","journal-title":"Kidney Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.3389\/fimmu.2018.03038","article-title":"Germinal center alloantibody responses mediate progression of chronic allograft injury","volume":"9","author":"Chhabra","year":"2018","journal-title":"Front. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12882-019-1672-8","article-title":"Treatment of chronic active antibody-mediated rejection in renal transplant recipients - a single center retrospective study","volume":"21","author":"Chiu","year":"2020","journal-title":"BMC Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (Anti-Interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients","volume":"17","author":"Choi","year":"2017","journal-title":"Am. J. Transpl."},{"key":"B23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/tp.0000000000000545","article-title":"Memory B cells in transplantation","volume":"99","author":"Chong","year":"2015","journal-title":"Transplantation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.trim.2014.08.005","article-title":"Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy","volume":"31","author":"Chung","year":"2014","journal-title":"Transpl. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1097\/01.Tp.0000443226.74584.03","article-title":"High dose intravenous immunoglobulin therapy for donor-specific antibodies in kidney transplant recipients with acute and chronic graft dysfunction","volume":"97","author":"Cooper","year":"2014","journal-title":"Transplantation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1111\/ajt.13377","article-title":"A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion","volume":"15","author":"Cordoba","year":"2015","journal-title":"Am. J. Transpl."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year","volume":"15","author":"Cornell","year":"2015","journal-title":"Am. J. Transpl."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3389\/fimmu.2019.02071","article-title":"CXCR5+PD1+ICOS+ Circulating T Follicular Helpers Are Associated With de novo Donor-Specific Antibodies After Renal Transplantation","volume":"10","author":"Danger","year":"2019","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3389\/fimmu.2017.00641","article-title":"Belatacept does not inhibit follicular T cell-dependent B-cell differentiation in kidney transplantation","volume":"8","author":"De Graav","year":"2017","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3389\/fimmu.2017.00306","article-title":"IL-21 receptor antagonist inhibits differentiation of B cells toward plasmablasts upon alloantigen stimulation","volume":"8","author":"De Leur","year":"2017","journal-title":"Front. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.humimm.2016.05.021","article-title":"Pathogenesis of non-HLA antibodies in solid organ transplantation: where do we stand?","volume":"77","author":"Delville","year":"2016","journal-title":"Hum. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00467-017-3712-6","article-title":"Biomarkers to detect rejection after kidney transplantation","volume":"33","author":"Dharnidharka","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/TP.0b013e3182081333","article-title":"The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo","volume":"91","author":"Diwan","year":"2011","journal-title":"Transplantation"},{"key":"B34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1681\/asn.2020071106","article-title":"A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection","volume":"32","author":"Doberer","year":"2020","journal-title":"Jasn"},{"key":"B35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/tp.0000000000003247","article-title":"CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection","volume":"105","author":"Doberer","year":"2020","journal-title":"Transplantation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1111\/j.1600-6143.2009.02799.x","article-title":"Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure","volume":"9","author":"Einecke","year":"2009","journal-title":"Am. J. Transpl."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/ajt.14222","article-title":"Proteasome inhibitor carfilzomib-based therapy for antibody-mediated rejection of the pulmonary allograft: use and short-term findings","volume":"17","author":"Ensor","year":"2017","journal-title":"Am. J. Transpl."},{"key":"B38","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/ajt.14528","article-title":"Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial","volume":"18","author":"Eskandary","year":"","journal-title":"Am. J. Transpl."},{"key":"B39","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1681\/asn.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection","volume":"29","author":"Eskandary","year":"","journal-title":"Jasn"},{"key":"B40","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/TP.0b013e31827d62e3","article-title":"Incidence and impact of de novo donor-specific alloantibody in primary renal allografts","volume":"95","author":"Everly","year":"2013","journal-title":"Transplantation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1681\/asn.2019030304","article-title":"Pretransplant desensitization with costimulation blockade and proteasome inhibitor reduces DSA and delays antibody-mediated rejection in highly sensitized nonhuman primate kidney transplant recipients","volume":"30","author":"Ezekian","year":"2019","journal-title":"Jasn"},{"key":"B42","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.ajkd.2015.03.033","article-title":"Humoral immune response and allograft function in kidney transplantation","volume":"66","author":"Filippone","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrneph.2012.238","article-title":"Assessing and improving the health-related quality of life of patients with ESRD","volume":"8","author":"Finkelstein","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/nrneph.2013.183","article-title":"Targeting co-stimulatory pathways: transplantation and autoimmunity","volume":"10","author":"Ford","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/TP.0b013e3181e065de","article-title":"Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure","volume":"90","author":"Gaston","year":"2010","journal-title":"Transplantation"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1111\/j.1523-1755.2005.00696.x","article-title":"The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation","volume":"68","author":"Gill","year":"2005","journal-title":"Kidney Int."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1111\/j.1600-6143.2007.01895.x","article-title":"Transplant glomerulopathy: subclinical incidence and association with alloantibody","volume":"7","author":"Gloor","year":"2007","journal-title":"Am. J. Transpl."},{"key":"B49","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1600-6143.2009.02985.x","article-title":"Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation","volume":"10","author":"Gloor","year":"2010","journal-title":"Am. J. Transpl."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1111\/ajt.15397","article-title":"Safety and efficacy of eculizumab for the prevention of antibody\u2010mediated rejection after deceased\u2010donor kidney transplantation in patients with preformed donor\u2010specific antibodies","volume":"19","author":"Glotz","year":"2019","journal-title":"Am. J. Transpl."},{"key":"B51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fimmu.2019.00235","article-title":"C5b9 deposition in glomerular capillaries is associated with poor kidney allograft survival in antibody-mediated rejection","volume":"10","author":"Goutaudier","year":"2019","journal-title":"Front. Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1681\/asn.2014040326","article-title":"Non-complement-binding de novo donor-specific anti-HLA antibodies and kidney allograft survival","volume":"27","author":"Guidicelli","year":"2016","journal-title":"Jasn"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1097\/01.tp.0000442503.85766.91","article-title":"Late antibody-mediated rejection in renal allografts","volume":"97","author":"Gupta","year":"2014","journal-title":"Transplantation"},{"key":"B54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/mnh.0000000000000398","article-title":"Evolving criteria for the diagnosis of antibody-mediated rejection in renal allografts","volume":"27","author":"Haas","year":"","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody\u2010mediated rejection, and prospects for integrative endpoints for next\u2010generation clinical trials","volume":"18","author":"Haas","year":"2018","journal-title":"Am. J. Transpl."},{"key":"B56","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.kint.2016.10.040","article-title":"Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent\/recurrent versus de novo donor-specific antibodies","volume":"91","author":"Haas","year":"2017","journal-title":"Kidney Int."},{"key":"B57","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions","volume":"14","author":"Haas","year":"2014","journal-title":"Am. J. Transpl."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1111\/ajt.15088","article-title":"The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts","volume":"18","author":"Haas","year":"","journal-title":"Am. J. Transpl."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1681\/asn.2014060588","article-title":"Disappearance of T Cell-Mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients","volume":"26","author":"Halloran","year":"2015","journal-title":"Jasn"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1111\/j.1600-6143.2010.03268.x","article-title":"An integrated view of molecular changes, histopathology and outcomes in kidney transplants","volume":"10","author":"Halloran","year":"2010","journal-title":"Am. J. Transpl."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/ajt.15178","article-title":"Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas","volume":"19","author":"Halloran","year":"2019","journal-title":"Am. J. Transpl."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1111\/ajt.12465","article-title":"Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM)","volume":"13","author":"Halloran","year":"2013","journal-title":"Am. J. Transpl."},{"key":"B63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/ajt.15274","article-title":"OPTN\/SRTR 2017 annual data report: kidney","volume":"19","author":"Hart","year":"2019","journal-title":"Am. J. Transpl."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16352","article-title":"i\u2010IFTA and chronic active T cell-mediated rejection: a tale of 2 (DeKAF) cohorts","author":"Helgeson","year":"2020","journal-title":"Am. J. Transpl."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1600-6143.2011.03970.x","article-title":"Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies","volume":"12","author":"Hidalgo","year":"2012","journal-title":"Am. J. Transpl."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1111\/j.1600-6143.2010.03201.x","article-title":"NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection","volume":"10","author":"Hidalgo","year":"2010","journal-title":"Am. J. Transpl."},{"key":"B67","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1600-6143.2011.03836.x","article-title":"A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody","volume":"12","author":"Hirohashi","year":"2012","journal-title":"Am. J. Transpl."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1097\/tp.0000000000002560","article-title":"The impact of early clinical and subclinical T cell-mediated rejection after kidney transplantation","volume":"103","author":"Hoffman","year":"2019","journal-title":"Transplantation"},{"key":"B69","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1172\/JCI125773","article-title":"Cross-dressed dendritic cells sustain effector T cell responses in islet and kidney allografts","volume":"130","author":"Hughes","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B70","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s40425-019-0653-6","article-title":"Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment","volume":"7","author":"Hurkmans","year":"2019","journal-title":"J. Immunotherapy Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/tp.0000000000002594","article-title":"Memory B cells and long-lived plasma cells","volume":"103","author":"Ionescu","year":"2019","journal-title":"Transplantation"},{"key":"B72","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/TP.0b013e3181837626","article-title":"Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels","volume":"86","author":"Issa","year":"2008","journal-title":"Transplantation"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1111\/ajt.15881","article-title":"Reversing donor\u2010specific antibody responses and antibody\u2010mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients","volume":"20","author":"Jain","year":"2020","journal-title":"Am. J. Transpl."},{"key":"B74","article-title":"Clazakizumab (Anti-IL-6 monoclonal) as an agent to reduce donor specific hla antibodies (DSA) and improve outcomes in patients with chronic & active antibody-mediated rejection post-kidney transplantation (NCT03380377) [abstract]","volume":"20","author":"Jordan","year":"2020","journal-title":"Am. J. Transpl."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1097\/txd.0000000000000821","article-title":"Donor-derived cell-free DNA identifies antibody-mediated rejection in donor specific antibody positive kidney transplant recipients","volume":"4","author":"Jordan","year":"2018","journal-title":"Transplant. direct"},{"key":"B76","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/tp.0000000000001452","article-title":"Interleukin-6, A cytokine critical to mediation of inflammation, autoimmunity and allograft rejection","volume":"101","author":"Jordan","year":"2017","journal-title":"Transplantation"},{"key":"B77","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/ctr.12345","article-title":"Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab","volume":"28","author":"Kahwaji","year":"2014","journal-title":"Clin. Transpl."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1097\/txd.0000000000001061","article-title":"Donor-derived cell-free DNA and the prediction of BK virus-associated nephropathy","volume":"6","author":"Kant","year":"2020","journal-title":"Transplant. direct"},{"key":"B79","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/tp.0000000000002482","article-title":"Donor-specific cell-free DNA as a biomarker in solid organ transplantation. A systematic review","volume":"103","author":"Knight","year":"2019","journal-title":"Transplantation"},{"key":"B80","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1038\/s41467-019-13113-5","article-title":"Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants","volume":"10","author":"Koenig","year":"2019","journal-title":"Nat. Commun."},{"key":"B81","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1681\/asn.2020040433","article-title":"Missing self-induced activation of NK cells combines with non-complement-fixing donor-specific antibodies to accelerate kidney transplant loss in chronic antibody-mediated rejection","volume":"32","author":"Koenig","year":"2021","journal-title":"Jasn"},{"key":"B82","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.immuni.2013.06.011","article-title":"Repression of the transcription factor Bach2 contributes to predisposition of IgG1 memory B cells toward plasma cell differentiation","volume":"39","author":"Kometani","year":"2013","journal-title":"Immunity"},{"key":"B83","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial","volume":"17","author":"Kulkarni","year":"2017","journal-title":"Am. J. Transpl."},{"key":"B85","doi-asserted-by":"publisher","first-page":"663","DOI":"10.34067\/kid.0000182019","article-title":"Lack of histological and molecular signature response to tocilizumab in kidney transplants with chronic active antibody mediated rejection: a case series","volume":"1","author":"Kumar","year":"2020","journal-title":"Kidney360"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1681\/asn.2016070727","article-title":"Humoral compensation after bortezomib treatment of allosensitized recipients","volume":"28","author":"Kwun","year":"2017","journal-title":"Jasn"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1681\/asn.2018121254","article-title":"Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use","volume":"30","author":"Kwun","year":"2019","journal-title":"Jasn"},{"key":"B88","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ajt.16004","article-title":"Superior inhibition of alloantibody responses with selective CD28 blockade is CTLA\u20104 dependent and T follicular helper cell specific","volume":"21","author":"La Muraglia","year":"2020","journal-title":"Am. J. Transpl."},{"key":"B89","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.trre.2019.06.003","article-title":"Follicular helper T cells and humoral response in organ transplantation","volume":"33","author":"Laguna-Goya","year":"2019","journal-title":"Transplant. Rev."},{"key":"B90","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1600-6143.2010.03283.x","article-title":"Long-term renal allograft survival in the United States: a critical reappraisal","volume":"11","author":"Lamb","year":"2011","journal-title":"Am. J. Transpl."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1681\/asn.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"Jasn"},{"key":"B92","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1681\/asn.2014111120","article-title":"IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury","volume":"27","author":"Lefaucheur","year":"2016","journal-title":"Jasn"},{"key":"B93","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.kint.2018.10.028","article-title":"Costimulatory blockade molecules and B-cell-mediated immune response: current knowledge and perspectives","volume":"95","author":"Leibler","year":"2019","journal-title":"Kidney Int."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1681\/asn.2017060679","article-title":"Control of humoral response in renal transplantation by belatacept depends on a direct effect on B cells and impaired T follicular helper-B cell crosstalk","volume":"29","author":"Leibler","year":"2018","journal-title":"Jasn"},{"key":"B95","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/tp.0000000000000310","article-title":"Donor-specific antibodies, C4d and their relationship with the prognosis of transplant glomerulopathy","volume":"99","author":"Lesage","year":"2015","journal-title":"Transplantation"},{"key":"B96","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.kint.2017.09.023","article-title":"Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation","volume":"93","author":"Li","year":"2018","journal-title":"Kidney Int."},{"key":"B97","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.kint.2017.08.008","article-title":"Novel aspects of epitope matching and practical application in kidney transplantation","volume":"93","author":"Lim","year":"2018","journal-title":"Kidney Int."},{"key":"B98","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1111\/ajt.13865","article-title":"Interferon gamma and contact-dependent cytotoxicity are each rate limiting for natural killer cell-mediated antibody-dependent chronic rejection","volume":"16","author":"Lin","year":"2016","journal-title":"Am. J. Transpl."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1681\/asn.2020030320","article-title":"Coordinated circulating T follicular helper and activated B cell responses underlie the onset of antibody-mediated rejection in kidney transplantation","volume":"31","author":"Louis","year":"2020","journal-title":"Jasn"},{"key":"B100","doi-asserted-by":"publisher","first-page":"l4923","DOI":"10.1136\/bmj.l4923","article-title":"Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study","volume":"366","author":"Loupy","year":"2019","journal-title":"BMJ"},{"key":"B101","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1600-6143.2010.03364.x","article-title":"Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA)","volume":"11","author":"Loupy","year":"2011","journal-title":"Am. J. Transpl."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1681\/asn.2013111149","article-title":"Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection","volume":"25","author":"Loupy","year":"2014","journal-title":"Jasn"},{"key":"B103","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.trre.2017.01.002","article-title":"A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection","volume":"31","author":"Macklin","year":"2017","journal-title":"Transplant. Rev."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1111\/ajt.15364","article-title":"Safety and efficacy of eculizumab in the prevention of antibody\u2010mediated rejection in living\u2010donor kidney transplant recipients requiring desensitization therapy: a randomized trial","volume":"19","author":"Marks","year":"2019","journal-title":"Am. J. Transpl."},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16391","article-title":"Do anti\u2010IL\u20106R blockers have a beneficial effect in the treatment of antibody\u2010mediated rejection resistant to standard therapy after kidney transplantation?","volume":"21","author":"Massat","year":"2020","journal-title":"Am. J. Transpl."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1111\/ajt.14349","article-title":"Belatacept-resistant rejection is associated with CD28+ memory CD8 T cells","volume":"17","author":"Mathews","year":"2017","journal-title":"Am. J. Transpl."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e12945","DOI":"10.1111\/ctr.12945","article-title":"Kidney allograft surveillance biopsy practices across US transplant centers: a UNOS survey","volume":"31","author":"Mehta","year":"2017","journal-title":"Clin. Transpl."},{"key":"B108","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1600-6143.2006.01635.x","article-title":"Infiltrates in protocol biopsies from renal allografts","volume":"7","author":"Mengel","year":"2007","journal-title":"Am. J. Transpl."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1681\/asn.2012070664","article-title":"Donor-specific antibodies adversely affect kidney allograft outcomes","volume":"23","author":"Mohan","year":"2012","journal-title":"Jasn"},{"key":"B110","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1111\/ajt.13871","article-title":"Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study","volume":"16","author":"Montgomery","year":"2016","journal-title":"Am. J. Transpl."},{"key":"B111","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/TP.0b013e31823bb647","article-title":"Early subclinical rejection as a risk factor for late chronic humoral rejection","volume":"93","author":"Moreso","year":"2012","journal-title":"Transplantation"},{"key":"B112","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial","volume":"18","author":"Moreso","year":"2018","journal-title":"Am. J. Transpl."},{"key":"B113","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1681\/asn.2015010062","article-title":"Proteinuria as a noninvasive marker for renal allograft histology and failure: an observational cohort study","volume":"27","author":"Naesens","year":"2016","journal-title":"Jasn"},{"key":"B114","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat. Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/tp.0000000000000869","article-title":"The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients","volume":"100","author":"O\u02bcLeary","year":"2016","journal-title":"Transplantation"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1681\/asn.2004121092","article-title":"Impact of cadaveric renal transplantation on survival in patients listed for transplantation","volume":"16","author":"Oniscu","year":"2005","journal-title":"Jasn"},{"key":"B118","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ekir.2019.01.018","article-title":"Glomerular C3 deposition is an independent risk factor for allograft failure in kidney transplant recipients with transplant glomerulopathy","volume":"4","author":"Panzer","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.ekir.2019.04.011","article-title":"Donor-specific antibodies in the absence of rejection are not a risk factor for allograft failure","volume":"4","author":"Parajuli","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"B120","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/tp.0000000000000132","article-title":"Differential effect of bortezomib on HLA class I and class II antibody","volume":"98","author":"Philogene","year":"2014","journal-title":"Transplantation"},{"key":"B121","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12882-018-1057-4","article-title":"Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection","volume":"19","author":"Pi\u00f1eiro","year":"2018","journal-title":"BMC Nephrol."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16463","article-title":"Long\u2010term kidney transplant graft survival-Making progress when most needed","author":"Poggio","year":"","journal-title":"Am. J. Transpl."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2215\/cjn.04710420","article-title":"Systematic review and meta-analysis of native kidney biopsy complications","volume":"15","author":"Poggio","year":"","journal-title":"Cjasn"},{"key":"B124","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3389\/fimmu.2016.00585","article-title":"The impact of HLA class I-specific killer cell immunoglobulin-like receptors on antibody-dependent natural killer cell-mediated cytotoxicity and organ allograft rejection","volume":"7","author":"Rajalingam","year":"2016","journal-title":"Front. Immunol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.humimm.2016.01.018","article-title":"Current outcomes of chronic active antibody mediated rejection - a large single center retrospective review using the updated BANFF 2013 criteria","volume":"77","author":"Redfield","year":"2016","journal-title":"Hum. Immunol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1111\/ajt.15514","article-title":"Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti\u2010 CD 20 monoclonal antibody for the desensitization of candidates for renal transplant","volume":"19","author":"Redfield","year":"2019","journal-title":"Am. J. Transpl."},{"key":"B127","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/s0140-6736(18)32473-5","article-title":"Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort","volume":"393","author":"Reindl-Schwaighofer","year":"2019","journal-title":"The Lancet"},{"key":"B128","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/TP.0b013e31825d1587","article-title":"The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review","volume":"94","author":"Roberts","year":"2012","journal-title":"Transplantation"},{"key":"B129","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12882-019-1385-z","article-title":"Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection","volume":"20","author":"Sablik","year":"2019","journal-title":"BMC Nephrol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/ki.2013.465","article-title":"Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure","volume":"85","author":"Sapir-Pichhadze","year":"2014","journal-title":"Kidney Int."},{"key":"B131","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/tp.0000000000000958","article-title":"One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation","volume":"100","author":"Sautenet","year":"2016","journal-title":"Transplantation"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1111\/ajt.15175","article-title":"Long\u2010term outcomes of eculizumab\u2010treated positive crossmatch recipients: allograft survival, histologic findings, and natural history of the donor\u2010specific antibodies","volume":"19","author":"Schinstock","year":"2019","journal-title":"Am. J. Transpl."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1111\/ajt.14161","article-title":"The value of protocol biopsies to identify patients with de novo donor-specific antibody at high risk for allograft loss","volume":"17","author":"Schinstock","year":"2017","journal-title":"Am. J. Transpl."},{"key":"B134","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/tp.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the transplantion society working group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"B135","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.kint.2020.08.020","article-title":"Preoperative Carfilzomib and Lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model","volume":"99","author":"Schroder","year":"2021","journal-title":"Kidney Int."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1111\/j.1600-6143.2005.00988.x","article-title":"Safety and adequacy of renal transplant protocol biopsies","volume":"5","author":"Schwarz","year":"2005","journal-title":"Am. J. Transpl."},{"key":"B137","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am. J. Transpl."},{"key":"B138","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/ajt.12150","article-title":"Molecular diagnosis of antibody-mediated rejection in human kidney transplants","volume":"13","author":"Sellar\u00e9s","year":"2013","journal-title":"Am. J. Transplant."},{"key":"B139","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/tp.0000000000002895","article-title":"Impact of tocilizumab (Anti-IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection","volume":"104","author":"Shin","year":"2020","journal-title":"Transplantation"},{"key":"B140","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1681\/asn.2013101144","article-title":"Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss","volume":"26","author":"Sicard","year":"2015","journal-title":"Jasn"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.3389\/fimmu.2018.02548","article-title":"T cell allorecognition pathways in solid organ transplantation","volume":"9","author":"Siu","year":"2018","journal-title":"Front. Immunol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1111\/ajt.15822","article-title":"High levels of dd\u2010cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury","volume":"20","author":"Stites","year":"2020","journal-title":"Am. J. Transpl."},{"key":"B143","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/ki.2010.437","article-title":"De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection","volume":"79","author":"Sun","year":"2011","journal-title":"Kidney Int."},{"key":"B144","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1053\/j.ajkd.2017.09.021","article-title":"HLA epitope matching in kidney transplantation: an overview for the general nephrologist","volume":"71","author":"Sypek","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"B145","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.3389\/fimmu.2019.02306","article-title":"Therapeutic modulation of the complement system in kidney transplantation: clinical indications and emerging drug leads","volume":"10","author":"Tatapudi","year":"2019","journal-title":"Front. Immunol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/ajt.15613","article-title":"A prospective, iterative, adaptive trial of carfilzomib\u2010based desensitization","volume":"20","author":"Tremblay","year":"2020","journal-title":"Am. J. Transpl."},{"key":"B147","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1097\/tp.0000000000002141","article-title":"Summary of 2017 FDA public workshop","volume":"102","author":"Velidedeoglu","year":"2018","journal-title":"Transplantation"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1111\/ajt.13663","article-title":"C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study","volume":"16","author":"Viglietti","year":"2016","journal-title":"Am. J. Transpl."},{"key":"B149","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","article-title":"Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting","volume":"35","author":"Viola","year":"2021","journal-title":"Leukemia"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1097\/tp.0000000000002224","article-title":"T follicular regulatory cells and antibody responses in transplantation","volume":"102","author":"Wallin","year":"2018","journal-title":"Transplantation"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1097\/TP.0b013e318218e901","article-title":"Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition","volume":"91","author":"Walsh","year":"2011","journal-title":"Transplantation"},{"key":"B152","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1111\/j.1600-6143.2007.01995.x","article-title":"Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies","volume":"7","author":"Wavamunno","year":"2007","journal-title":"Am. J. Transpl."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am. J. Transpl."},{"key":"B154","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and determinants of progression to graft failure in kidney allograft recipients WithDe NovoDonor-specific antibody","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am. J. Transpl."},{"key":"B155","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/MOT.0b013e3283626149","article-title":"Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation","volume":"18","author":"Wiebe","year":"2013","journal-title":"Curr. Opin. Organ. Transplant."},{"key":"B156","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1111\/ajt.12478","article-title":"Class II HLA epitope matching-A strategy to MinimizeDe NovoDonor-specific antibody development and improve outcomes","volume":"13","author":"Wiebe","year":"2013","journal-title":"Am. J. Transpl."},{"key":"B157","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1681\/asn.2017030287","article-title":"Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development","volume":"28","author":"Wiebe","year":"2017","journal-title":"Jasn"},{"key":"B158","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/TP.0b013e3182543950","article-title":"De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy","volume":"94","author":"Willicombe","year":"2012","journal-title":"Transplantation"},{"key":"B159","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/ajt.15634","article-title":"Proteasomal adaptations underlying carfilzomib\u2010resistance in human bone marrow plasma cells","volume":"20","author":"Woodle","year":"2020","journal-title":"Am. J. Transpl."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1681\/asn.2017040443","article-title":"Targeting plasma cells with proteasome inhibitors: principles from primates","volume":"28","author":"Woodle","year":"2017","journal-title":"Jasn"},{"key":"B161","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/TP.0b013e318203fd26","article-title":"C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation","volume":"91","author":"Yabu","year":"2011","journal-title":"Transplantation"},{"key":"B162","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.kint.2018.08.041","article-title":"In the absence of natural killer cell activation donor-specific antibody mediates chronic, but not acute, kidney allograft rejection","volume":"95","author":"Yagisawa","year":"2019","journal-title":"Kidney Int."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3389\/fimmu.2017.01510","article-title":"T follicular helper cells as a new target for immunosuppressive therapies","volume":"8","author":"Yan","year":"2017","journal-title":"Front. Immunol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1097\/tp.0000000000000699","article-title":"C1q binding activity of de novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection","volume":"99","author":"Yell","year":"2015","journal-title":"Transplantation"},{"key":"B165","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrneph.2016.88","article-title":"The importance of non-HLA antibodies in transplantation","volume":"12","author":"Zhang","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2215\/cjn.00700117","article-title":"Donor-specific antibodies in kidney transplant recipients","volume":"13","author":"Zhang","year":"2018","journal-title":"Cjasn"},{"key":"B167","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1600-6143.2011.03770.x","article-title":"Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance","volume":"12","author":"Zhao","year":"2012","journal-title":"Am. J. Transplant. : official J. Am. Soc. Transplant. Am. Soc. Transpl. Surgeons"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.651222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T22:13:51Z","timestamp":1619907231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.651222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":167,"alternative-id":["10.3389\/fphar.2021.651222"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.651222","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"article-number":"651222"}}